- Home
- OCC vs NRXP Comparison
OCC vs NRXP Comparison
Compare OCC & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCC
- NRXP
- Stock Information
- Founded
- OCC 1983
- NRXP 2015
- Country
- OCC United States
- NRXP United States
- Employees
- OCC N/A
- NRXP N/A
- Industry
- OCC Telecommunications Equipment
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- OCC Industrials
- NRXP Health Care
- Exchange
- OCC Nasdaq
- NRXP Nasdaq
- Market Cap
- OCC 42.9M
- NRXP 51.3M
- IPO Year
- OCC 1996
- NRXP N/A
- Fundamental
- Price
- OCC $4.25
- NRXP $2.28
- Analyst Decision
- OCC
- NRXP Strong Buy
- Analyst Count
- OCC 0
- NRXP 3
- Target Price
- OCC N/A
- NRXP $31.67
- AVG Volume (30 Days)
- OCC 68.6K
- NRXP 458.6K
- Earning Date
- OCC 03-12-2025
- NRXP 03-27-2025
- Dividend Yield
- OCC N/A
- NRXP N/A
- EPS Growth
- OCC N/A
- NRXP N/A
- EPS
- OCC N/A
- NRXP N/A
- Revenue
- OCC $66,674,099.00
- NRXP N/A
- Revenue This Year
- OCC N/A
- NRXP N/A
- Revenue Next Year
- OCC N/A
- NRXP N/A
- P/E Ratio
- OCC N/A
- NRXP N/A
- Revenue Growth
- OCC N/A
- NRXP N/A
- 52 Week Low
- OCC $2.02
- NRXP $1.10
- 52 Week High
- OCC $7.00
- NRXP $7.33
- Technical
- Relative Strength Index (RSI)
- OCC 43.84
- NRXP 38.85
- Support Level
- OCC $4.21
- NRXP $2.80
- Resistance Level
- OCC $5.10
- NRXP $3.07
- Average True Range (ATR)
- OCC 0.47
- NRXP 0.29
- MACD
- OCC -0.12
- NRXP -0.10
- Stochastic Oscillator
- OCC 5.06
- NRXP 2.52
About OCC Optical Cable Corporation
Optical Cable Corp manufactures tight-buffered fiber optic & copper data communication cables, data communication connectivity solutions for enterprise markets, and customized solutions for specialty use & harsh environments. Its products and services include designs and customized products for specialty applications and harsh environments, cabling, connectors, patch cords, assemblies, racks, cabinets, datacom enclosures, patch panels, faceplates, and multi-media boxes. The company supplies its products and services to industries such as the military, industrial, mining, petrochemical, renewable energy and broadcast applications, and for the wireless carrier market.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.